Marija Bojic

Dr. Marija Bojic

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Manuela SchmidingerManuela Schmidinger
Manuela Schmidinger
CZChristoph C. Zielinski
Christoph C. Zielinski
UVUrsula M. Vogl
Ursula M. Vogl
ABAndja Bojic
Andja Bojic
MBMarija Bojic
Marija Bojic
HSHerwig Schmidinger
Herwig Schmidinger
Purpose: Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs of myocardial damage. Patients and Methods: In this observational, single-center study, all patients intended for TKI treatment were analyzed for coronary artery disease (CAD) risk factors, history or evidence of CAD, hypertension, rhythm disturbances, and heart failure. Monitoring included assessment of symptoms, ECGs, and biochemical markers (ie, creatine kinase-MB, troponin T). Echocardiography was performed at baseline in selected patients and in all patients who experienced a cardiac event. A cardiac event was defined as the occurrence of increased enzymes if normal at baseline, symptomatic arrhythmia that required treatment, new left ventricular dysfunction, or acute coronary syndrome. Results: A total of 86 patients were treated with either sunitinib or sorafenib. Among 74 eligible patients, 33.8% experienced a cardiac event, 40.5% had ECG changes, and 18% were symptomatic. Seven patients (9.4%) were seriously compromised and required intermediate care and/or intensive care admission. All patients recovered after cardiovascular management (ie, medication, coronary angiography, pacemaker implantation, heart surgery) and were considered eligible for TKI continuation. Statistically, there was no significant survival difference between patients who experienced a cardiac event and those who did not experience a cardiac event. Conclusion: Our observations indicate that cardiac damage from TKI treatment is a largely underestimated phenomenon but is manageable if patients have careful cardiovascular monitoring and cardiac treatment at the first signs of myocardial damage.

15 September 2010 in Cancer
Verified
Journal Article
Open access
PDF file
Manuela SchmidingerManuela Schmidinger
Manuela Schmidinger
UVUrsula M. Vogl
Ursula M. Vogl
MBMarija Bojic
Marija Bojic
WLWolfgang Lamm
Wolfgang Lamm
HHHarald Heinzl
Harald Heinzl
CZChristoph C. Zielinski
Christoph C. Zielinski
BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important antitumor activity in metastatic renal cell carcinoma (mRCC). Hypothyroidism constitutes a commonly reported side effect of both drugs, and particularly of sunitinib. The objective of this analysis was to investigate whether the occurrence of hypothyroidism during treatment with sunitinib and sorafenib affects the outcome of patients with mRCC.METHODS: Eighty‐seven consecutive patients with mRCC who were to receive treatment with sunitinib or sorafenib were included in a prospective analysis. Thyroid function was assessed in each patient every 4 weeks during the first 2 months of treatment and every 2 to 4 months thereafter. Assessment included serum levels of thyroid‐stimulating hormone (TSH), tri‐iodthyronine (T3), and thyroxine (T4). Subclinical hypothyroidism was defined as an increase in TSH above the upper limit of normal (>3.77 μM/mL) with normal T3 and T4 levels.RESULTS: Subclinical hypothyroidism was evident in 5 patients at baseline and occurred in 30 patients (36.1%) within the first 2 months after treatment initiation. There was a statistically significant correlation between the occurrence of subclinical hypothyroidism during treatment and the rate of objective remission (hypothyroid patients vs euthyroid patients: 28.3% vs 3.3%, respectively; P < .001) and the median duration of survival (not reached vs 13.9 months, respectively; hazard ratio, 0.35; 95% confidence interval, 0.14‐0.85; P = .016). In multivariate analysis, the development of subclinical hypothyroidism was identified as an independent predictor of survival (hazard ratio, 0.31; P = .014).CONCLUSIONS: The current results indicated that hypothyroidism may serve as a predictive marker of treatment outcome in patients with mRCC. Thus, the interpretation of hypothyroidism during treatment with sunitinib and sorafenib as an unwanted side effect should be reconsidered. Cancer 2011. © 2010 American Cancer Society.

6 July 2014 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
A(Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
PWPhilipp Wohlfarth
Philipp Wohlfarth
TSThomas Staudinger
Thomas Staudinger
WSWolfgang R. Sperr
Wolfgang R. Sperr
ABAndja Bojic
Andja Bojic
PSPeter Schellongowski
Peter Schellongowski

27 February 2013 in Transplantation
Verified
Journal Article
Closed access
UVUrsula M. Vogl
Ursula M. Vogl
KNKazuhiro Nagayama
Kazuhiro Nagayama
MBMarija Bojic
Marija Bojic
MHMir Ali Reza Hoda
Mir Ali Reza Hoda
WKWalter Klepetko
Walter Klepetko
WRWerner Rabitsch
Werner Rabitsch
Bronchiolitis obliterans (BO) is a detrimental late pulmonary complication after allogeneic hematopoietic stem cell transplantation (HCT) associated with chronic graft-versus-host disease (cGvHD). When systemic immunosuppressive treatment fails to improve, severe BO patients should be considered for lung transplantation (LuTX). We present seven patients undergoing LuTX for severe refractory BO after HCT. Seven patients with hematologic malignancies developed severe cGvHD with lung involvement presenting as BO after allogeneic HCT. Evaluation for LuTX was initiated after failure of a median of 4 immunosuppressive regimens. Between 1996 and 2012, seven patients with severe refractory BO were evaluated for LuTX. The median time from HCT to diagnosis of chronic lung GvHD was 8.2 months (range, 3.7-16.6). At a median time of 18.1 months (range, 6-120) after diagnosis of BO, six patients received a bilateral sequential LuTX, and one patient received a single LuTX. Six postoperative courses were uneventful; the patient with single LuTX died from septic multiorgan failure. Three LuTX recipients had a mild acute rejection after one to three months after LuTX, and one patient experienced fatal chronic rejection and hemolytic uremic syndrome. At present, three (43%) LuTX recipients remain alive at a median observation time of 26 months (range, 1 month-16 years) after LuTX. The median overall survival from LuTX was 24 months (95% CI, 0.5-78); the median overall survival time after allogeneic HCT is 98 months (95% CI, 46-198). This case series illustrates that LuTX is a possible therapeutic option for selected patients with severe treatment-refractory BO.

7 September 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
UVUrsula M Vogl
Ursula M Vogl
MBMarija Bojic
Marija Bojic
WLWolfgang Lamm
Wolfgang Lamm
JFJosa M Frischer
Josa M Frischer
OPOskar Pichelmayer
Oskar Pichelmayer
Manuela SchmidingerManuela Schmidinger
Manuela Schmidinger
In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents.

20 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BBBernhard Bielesz
Bernhard Bielesz
TRThomas Reiter
Thomas Reiter
RMRodrig Marculescu
Rodrig Marculescu
AGAndreas Gleiss
Andreas Gleiss
MBMarija Bojic
Marija Bojic
DCDaniel Cejka
Daniel Cejka
Vascular calcification is a component of cardiovascular disease, which is leading cause of death in patients with chronic kidney disease (CKD). A functional assay (T50-test) measuring the propensity of human serum to calcify associates with mortality and cardiovascular events in CKD patients. Calcification propensity is known to increase with CKD stage. We investigated whether the T50 readout is directly dependent on excretory kidney function (eGFR) or rather explained by deranged parameters of bone and mineral metabolism in the course of CKD. T50, along with markers implicated in calcification and mineral metabolism, were measured in a cross-sectional cohort of 118 patients with CKD stage 1–5. Associations of T50 with measured parameters were analysed and partial correlations performed to test to which extent the association of T50 with eGFR can be attributed to variation of these parameters. T50 correlates with eGFR, but serum levels of phosphate and calcium largely explain this association. Phosphate, magnesium, fetuin A, albumin, bicarbonate, and serum cross-laps but not Parathyroid Hormone or Fibroblast Growth Factor 23 are associated with T50 in multivariate adjusted models. These findings indicate that T50 values depend mainly on the concentration of promoters and inhibitors of calcification in serum, but not excretory kidney function.